HUE053816T2 - Rivasztigmin tartalmú elnyújtott felszabadulású gyógyszerészeti készítmény - Google Patents
Rivasztigmin tartalmú elnyújtott felszabadulású gyógyszerészeti készítményInfo
- Publication number
- HUE053816T2 HUE053816T2 HUE16786732A HUE16786732A HUE053816T2 HU E053816 T2 HUE053816 T2 HU E053816T2 HU E16786732 A HUE16786732 A HU E16786732A HU E16786732 A HUE16786732 A HU E16786732A HU E053816 T2 HUE053816 T2 HU E053816T2
- Authority
- HU
- Hungary
- Prior art keywords
- rivastigmine
- pharmaceutical composition
- release pharmaceutical
- containing sustained
- sustained
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150058759A KR101990951B1 (ko) | 2015-04-27 | 2015-04-27 | 리바스티그민 함유 서방출 의약조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE053816T2 true HUE053816T2 (hu) | 2021-07-28 |
Family
ID=57199589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE16786732A HUE053816T2 (hu) | 2015-04-27 | 2016-04-27 | Rivasztigmin tartalmú elnyújtott felszabadulású gyógyszerészeti készítmény |
Country Status (21)
Country | Link |
---|---|
US (1) | US10835497B2 (hu) |
EP (1) | EP3290023B1 (hu) |
JP (1) | JP6787928B2 (hu) |
KR (1) | KR101990951B1 (hu) |
CN (1) | CN107530290B (hu) |
AU (1) | AU2016255302B2 (hu) |
BR (1) | BR112017022478B1 (hu) |
CA (1) | CA2984235C (hu) |
CY (1) | CY1124339T1 (hu) |
DK (1) | DK3290023T3 (hu) |
ES (1) | ES2860694T3 (hu) |
HR (1) | HRP20210434T1 (hu) |
HU (1) | HUE053816T2 (hu) |
LT (1) | LT3290023T (hu) |
MX (1) | MX2017013481A (hu) |
PL (1) | PL3290023T3 (hu) |
PT (1) | PT3290023T (hu) |
RS (1) | RS61548B1 (hu) |
RU (1) | RU2727721C2 (hu) |
SI (1) | SI3290023T1 (hu) |
WO (1) | WO2016175546A2 (hu) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102209420B1 (ko) * | 2019-03-08 | 2021-01-29 | 에이치엘비제약 주식회사 | 리바스티그민의 일정한(0-차) 방출형 경구용 서방성 정제 조성물 |
CN112546037A (zh) * | 2020-12-08 | 2021-03-26 | 苏州大学 | 卡巴拉汀在制备抗辐射药中的应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL141762A0 (en) | 1998-10-01 | 2002-03-10 | Novartis Ag | New oral formulations |
AU6715600A (en) | 1999-08-26 | 2001-03-19 | Elan Corporation, Plc | Pharmaceutical formulations |
JP2003507416A (ja) | 1999-08-26 | 2003-02-25 | エラン コーポレイション ピーエルスィー | 医薬製剤 |
GB9923045D0 (en) | 1999-09-29 | 1999-12-01 | Novartis Ag | New oral formulations |
US20050163847A1 (en) * | 2004-01-21 | 2005-07-28 | Andrx Pharmaceuticals, Llc | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug |
AU2005320547B2 (en) | 2004-12-27 | 2009-02-05 | Eisai R & D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
RU2390354C2 (ru) | 2004-12-27 | 2010-05-27 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Препарат матричного типа с замедленным высвобождением, содержащий основное лекарственное средство или его соль, и способ его получения |
CA2605185A1 (en) * | 2005-04-06 | 2006-10-12 | Mallinckrodt Inc. | Matrix-based pulse release pharmaceutical formulation |
DK2508621T3 (en) * | 2005-11-29 | 2015-01-12 | Childrens Hosp Medical Center | Optimization and individualization of drug selection and dosage |
BRPI0621633A2 (pt) | 2006-05-12 | 2011-12-13 | Shire Llc | composição farmacêutica, método para tratar distúrbio de déficit de atenção por hiperatividade (adhd) e composição farmacêutica de liberação sustentada |
US8846100B2 (en) * | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
US8632805B2 (en) | 2008-06-20 | 2014-01-21 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations, method of manufacture, and use thereof |
US20100159001A1 (en) | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
CN102548544B (zh) * | 2009-10-09 | 2015-01-21 | 永进药品工业株式会社 | 同时具有速效特性和长效特性的药物组合物 |
CA2793777C (en) | 2010-03-31 | 2019-04-16 | Supernus Pharmaceuticals, Inc. | Formulations of mazindol |
EP2974720B1 (en) | 2013-03-15 | 2024-02-21 | Korea United Pharm. Inc. | Mosapride sustained-release preparation for providing pharmacological clinical effects with once-a-day administration |
-
2015
- 2015-04-27 KR KR1020150058759A patent/KR101990951B1/ko active IP Right Grant
-
2016
- 2016-04-27 LT LTEP16786732.4T patent/LT3290023T/lt unknown
- 2016-04-27 CN CN201680024737.4A patent/CN107530290B/zh active Active
- 2016-04-27 PL PL16786732T patent/PL3290023T3/pl unknown
- 2016-04-27 US US15/569,693 patent/US10835497B2/en active Active
- 2016-04-27 RS RS20210290A patent/RS61548B1/sr unknown
- 2016-04-27 MX MX2017013481A patent/MX2017013481A/es unknown
- 2016-04-27 SI SI201631161T patent/SI3290023T1/sl unknown
- 2016-04-27 EP EP16786732.4A patent/EP3290023B1/en active Active
- 2016-04-27 WO PCT/KR2016/004380 patent/WO2016175546A2/ko active Application Filing
- 2016-04-27 ES ES16786732T patent/ES2860694T3/es active Active
- 2016-04-27 RU RU2017136567A patent/RU2727721C2/ru active
- 2016-04-27 AU AU2016255302A patent/AU2016255302B2/en active Active
- 2016-04-27 BR BR112017022478-0A patent/BR112017022478B1/pt active IP Right Grant
- 2016-04-27 JP JP2017555575A patent/JP6787928B2/ja active Active
- 2016-04-27 HU HUE16786732A patent/HUE053816T2/hu unknown
- 2016-04-27 PT PT167867324T patent/PT3290023T/pt unknown
- 2016-04-27 DK DK16786732.4T patent/DK3290023T3/da active
- 2016-04-27 CA CA2984235A patent/CA2984235C/en active Active
-
2021
- 2021-03-16 HR HRP20210434TT patent/HRP20210434T1/hr unknown
- 2021-04-14 CY CY20211100324T patent/CY1124339T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP3290023A2 (en) | 2018-03-07 |
PT3290023T (pt) | 2021-03-24 |
MX2017013481A (es) | 2018-05-17 |
KR101990951B1 (ko) | 2019-06-20 |
AU2016255302B2 (en) | 2021-03-04 |
WO2016175546A2 (ko) | 2016-11-03 |
SI3290023T1 (sl) | 2021-08-31 |
BR112017022478B1 (pt) | 2023-11-21 |
RU2017136567A3 (hu) | 2019-09-19 |
US10835497B2 (en) | 2020-11-17 |
CN107530290B (zh) | 2021-04-27 |
JP2018514530A (ja) | 2018-06-07 |
US20180125785A1 (en) | 2018-05-10 |
CN107530290A (zh) | 2018-01-02 |
JP6787928B2 (ja) | 2020-11-18 |
KR20160127405A (ko) | 2016-11-04 |
EP3290023B1 (en) | 2021-02-17 |
RS61548B1 (sr) | 2021-04-29 |
BR112017022478A2 (pt) | 2018-07-10 |
LT3290023T (lt) | 2021-03-25 |
HRP20210434T1 (hr) | 2021-04-30 |
EP3290023A4 (en) | 2018-12-19 |
DK3290023T3 (da) | 2021-04-12 |
ES2860694T3 (es) | 2021-10-05 |
CY1124339T1 (el) | 2022-07-22 |
PL3290023T3 (pl) | 2021-08-30 |
AU2016255302A1 (en) | 2017-12-07 |
CA2984235C (en) | 2023-02-21 |
CA2984235A1 (en) | 2016-11-03 |
WO2016175546A3 (ko) | 2016-12-22 |
RU2017136567A (ru) | 2019-05-27 |
RU2727721C2 (ru) | 2020-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL265360B (en) | Pharmaceutical composition | |
IL265260B (en) | pharmaceutical preparations | |
GB201506658D0 (en) | Pharmaceutical compounds | |
GB201504675D0 (en) | Pharmaceutical compounds | |
GB201517217D0 (en) | Pharmaceutical compounds | |
GB201506660D0 (en) | Pharmaceutical compounds | |
GB201517216D0 (en) | Pharmaceutical compounds | |
IL262654A (en) | Pharmacy preparation | |
IL265349A (en) | Pharmaceutical composition | |
HK1246641A1 (zh) | 緩釋性醫藥組合物 | |
GB201506933D0 (en) | Pharmaceutical compounds | |
GB201502567D0 (en) | Pharmaceutical compounds | |
IL263040A (en) | Pharmaceutical composition comprising eteplirsen | |
GB201521462D0 (en) | Pharmaceutical composition | |
GB201515310D0 (en) | Pharmaceutical composition | |
HK1245073A1 (zh) | 藥物組合物 | |
PL3454838T3 (pl) | Kompozycja farmaceutyczna | |
GB201615917D0 (en) | Pharmaceutical composition | |
GB201520862D0 (en) | Pharmaceutical composition | |
PL3290023T3 (pl) | Kompozycja farmaceutyczna o przedłużonym uwalnianiu zawierająca rywastygminę | |
GB201615914D0 (en) | Pharmaceutical composition | |
GB201615910D0 (en) | Pharmaceutical composition | |
IL265436B (en) | Pharmacy preparation | |
HUE057830T2 (hu) | Famitinib tartalmú gyógyszerkészítmény | |
IL265428A (en) | Pharmaceutical composition |